Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
6/30/18 cash was $38.6M (€33.1M) after burning $3.0M (€2.6M) during 2Q18. Guidance for 2H18 cash burn is $19.4M (€16.6M), implying projected a cash balance at 12/31/18 of $19.2M.
Transgene (TNG.PA), a biotech company that designs and develops virus-based immunotherapies, announces that the first patient has been dosed in a Phase 1 clinical trial in China, evaluating T101, a therapeutic vaccine based on Transgene’s immunotherapy technology for the treatment of chronic hepatitis B virus (HBV) infection. This product is a viral vector expressing the same suite of patented HBV antigens as in TG1050, currently in clinical development in Europe and North America.
T101 is being developed in China through Transgene’s[50/50]joint-venture with Tasly Pharmaceutical Group Co, Ltd.
The Phase 1 trial is a randomized, single-center, double-blind, placebo-controlled study evaluating T101 in patients who are currently being treated for chronic HBV infection with standard-of-care antiviral therapy… The trial will also evaluate the immunogenicity of the therapeutic vaccine in a patient population whose characteristics differ from European and North American patients (e.g. different modes of contamination, different population haplotypes), and who can be infected with different genotypes of the virus. This trial will include up to 36 patients. The first data readout from the study is expected at the beginning of 2019.
TNG.PA* starts phase-2 trial of TG4010 cancer vaccine in combination with Opdivo and chemotherapy in first-line, non-squamous NSCLC patients with low (or no) PD-L1 expression: